Atea Pharmaceuticals completes enrollment in Phase 3 C-FORWARD trial of bemnifosbuvir and ruzasvir for hepatitis C
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $351.37M | $48.63M | N/A | N/A |
| Cost of Revenue | $83.37M | $70.09M | $62.39M | $167.21M | $38.02M | $17.00K | $17.00K |
| Gross Profit | $-83.37M | $-70.09M | $-62.39M | $184.16M | $10.61M | $-17.00K | $-17.00K |
| Gross Margin | 0.00% | 0.00% | 0.00% | 52.41% | 21.82% | 0.00% | 0.00% |
| Operating Expenses | $109.58M | $94.07M | $68.26M | $45.78M | $21.64M | $14.59M | $9.46M |
| Operating Income | $-192.95M | $-164.16M | $-130.65M | $138.38M | $-11.03M | $-14.61M | $-9.48M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 39.38% | -22.68% | 0.00% | 0.00% |
| Net Income | $-168.38M | $-135.96M | $-115.91M | $121.19M | $-10.95M | $-13.46M | $-9.06M |
| Net Margin | 0.00% | 0.00% | 0.00% | 34.49% | -22.51% | 0.00% | 0.00% |
| EPS (Basic) | $-2.00 | $-1.63 | $-1.39 | $1.46 | $-0.13 | $-0.16 | $-0.90 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |